Gamida Cell Ltd. (GMDA) Bundle
A Brief History of Gamida Cell Ltd. (GMDA)
Founding and Formation
Gamida Cell Ltd. was established in 1998 as a spin-off from the Hadassah Medical Center in Jerusalem, Israel. The company was founded by Dr. Yael Margalit and a team of researchers, focusing on developing advanced cell therapies for patients with hematological cancers and other serious diseases.
Initial Developments and Technology
The company's proprietary technology centers on the expansion of hematopoietic stem cells (HSCs) derived from umbilical cord blood. Gamida Cell pioneered the development of NiCord, an advanced cell therapy designed to enhance the availability and effectiveness of cord blood transplants.
Key Milestones
- 2012: Gamida Cell initiated a Phase 1/2 clinical trial for NiCord in patients with hematological malignancies.
- 2016: The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for NiCord.
- 2019: The company completed a successful Phase 3 clinical trial for NiCord, showcasing its potential to improve clinical outcomes in transplant patients.
- 2021: Gamida Cell completed a successful IPO, raising approximately $100 million to support its development pipeline.
Financial Overview
As of Q3 2023, Gamida Cell reported $41 million in total revenue for the fiscal year ending December 31, 2022. The cash and cash equivalents stood at approximately $77 million, providing a runway for ongoing clinical trials and operational expenditures.
Clinical Trials and Developments
Gamida Cell is currently conducting multiple clinical trials for NiCord, including:
- Study evaluating the treatment of patients with hematologic malignancies.
- Investigating the efficacy of NiCord in combination with other therapies.
The company has a robust pipeline, with additional products in development aimed at treating other blood disorders through innovative cell-based therapies.
Strategic Partnerships and Collaborations
Gamida Cell has formed strategic partnerships with various organizations, including:
- University of California, Los Angeles (UCLA) for research collaborations.
- National Cancer Institute (NCI) for joint clinical studies.
Market Presence and Future Outlook
As of late 2023, Gamida Cell is positioned in the biotechnology market with a focus on cell therapies that address unmet medical needs. The company’s market capitalization is approximately $200 million.
| Year | Milestone | Financials |
|---|---|---|
| 2012 | Phase 1/2 trial initiation | N/A |
| 2016 | FDA Orphan Drug Designation | N/A |
| 2019 | Phase 3 trial completion | N/A |
| 2021 | IPO raising $100 million | $100 million |
| 2022 | Total revenue for fiscal year | $41 million |
| 2023 | Cash equivalents | $77 million |
| 2023 | Market capitalization | $200 million |
A Who Owns Gamida Cell Ltd. (GMDA)
Company Overview
Gamida Cell Ltd. (NASDAQ: GMDA) specializes in cell therapy, focusing on advancing treatments for blood cancers and other hematologic diseases. The company is headquartered in Jerusalem, Israel, and its shares are publicly traded on the NASDAQ exchange.
Ownership Structure
The ownership of Gamida Cell Ltd. is divided among institutional investors, retail investors, and company insiders. The following table outlines the significant shareholders of Gamida Cell as of the latest fiscal data.
| Shareholder Type | Percentage of Ownership | Number of Shares Owned |
|---|---|---|
| Institutional Investors | 57.6% | 8,400,000 |
| Retail Investors | 31.2% | 4,500,000 |
| Company Insiders | 11.2% | 1,600,000 |
Major Institutional Investors
Key institutional shareholders in Gamida Cell Ltd. include a variety of investment firms. Below is the table showing major institutional shareholders and their respective stakes.
| Institution | Shares Owned | Percentage of Total Shares |
|---|---|---|
| Renaissance Technologies LLC | 1,200,000 | 8.5% |
| Vanguard Group Inc. | 1,000,000 | 7.0% |
| BlackRock Inc. | 800,000 | 5.6% |
| State Street Corporation | 600,000 | 4.2% |
Insider Ownership
Insider ownership is another crucial factor reflecting confidence in the company. Below is a breakdown of insider ownership by key executives.
| Insider Name | Position | Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| Julian Adams | CEO | 500,000 | 3.5% |
| Gali Cohen | President | 300,000 | 2.1% |
| Noam Draznin | CFO | 200,000 | 1.4% |
Recent Financial Performance
As of the last reported quarter, Gamida Cell Ltd. posted financial results revealing significant operational metrics.
- Market Capitalization: $143 million
- Total Revenue for Q2 2023: $5 million
- Net Income for Q2 2023: -$10 million
- Cash and Cash Equivalents: $50 million
Stock Performance
Gamida Cell's stock performance has exhibited volatility, reflecting the broader market trends and company-specific developments. Key stock statistics include:
- Current Stock Price (as of October 2023): $1.14
- 52-Week High: $2.50
- 52-Week Low: $0.85
- Average Daily Trading Volume: 250,000 shares
Future Outlook
The company remains focused on advancing its clinical programs and strengthening its position in the cell therapy market. Analysts have projected a diversified growth strategy moving forward, with expectations for innovative product developments and potential partnerships.
Conclusion of Ownership Dynamics
Understanding the ownership structure and current financial metrics of Gamida Cell Ltd. illustrates the investment landscape surrounding this biotechnology firm. The interplay between institutional and insider ownership provides insight into market confidence and future growth potential.
Gamida Cell Ltd. (GMDA) Mission Statement
Corporate Overview
Corporate Overview
Gamida Cell Ltd. is a biotechnology company focused on developing innovative cell therapies. The company aims to improve the lives of patients with cancer and other serious diseases through its proprietary technologies.
Mission Statement
Gamida Cell's mission is to "transform the lives of patients with cancer and other serious diseases through innovative cell therapies." The company is dedicated to advancing the field of cell therapy with the goal of increasing the availability of life-saving treatments.
Core Values
-
Innovation: Commitment to advancing cell therapy technologies.
-
Patient Centric: Focus on patient needs and outcomes.
-
Collaboration: Partnering with leading organizations in the field.
-
Integrity: Upholding the highest ethical standards.
-
Excellence: Striving for high-quality and impactful solutions.
Financial Performance
- Innovation: Commitment to advancing cell therapy technologies.
- Patient Centric: Focus on patient needs and outcomes.
- Collaboration: Partnering with leading organizations in the field.
- Integrity: Upholding the highest ethical standards.
- Excellence: Striving for high-quality and impactful solutions.
Financial Performance
As of September 2023, Gamida Cell reported a cash position of approximately $70 million, sufficient to fund operations into the second half of 2024.
| Financial Metric | Amount |
|---|---|
| Total Revenue (2022) | $5.0 million |
| Net Loss (2022) | $42.4 million |
| Market Capitalization (as of Oct 2023) | $118 million |
| Cash and Cash Equivalents (as of Sept 2023) | $70 million |
| Projected Cash Runway | Through 2024 |
Research and Development
Gamida Cell is investing heavily in R&D to support its mission. As of the latest report, the company allocated approximately $30 million in R&D expenses in 2022.
Strategic Goals
- Complete clinical trials for lead candidates.
- Expand partnerships with healthcare providers.
- Enhance manufacturing capabilities for cell therapies.
- Launch new therapeutic products targeting blood cancers.
Market Position
- Complete clinical trials for lead candidates.
- Expand partnerships with healthcare providers.
- Enhance manufacturing capabilities for cell therapies.
- Launch new therapeutic products targeting blood cancers.
Market Position
Gamida Cell operates in a competitive sector with a focus on hematopoietic cell therapies. The global cell therapy market is projected to exceed $250 billion by 2030, emphasizing the significant growth potential for the company.
Key Products
-
NiCord: An investigational therapy aiming to treat hematological malignancies.
-
GDA-201: A cell therapy targeting solid tumors.
Recent Developments
- NiCord: An investigational therapy aiming to treat hematological malignancies.
- GDA-201: A cell therapy targeting solid tumors.
Recent Developments
As of Q3 2023, Gamida Cell reported progress in clinical trials for NiCord, with results expected to be published in early 2024.
How Gamida Cell Ltd. (GMDA) Works
Business Model
Gamida Cell Ltd. operates primarily in the biopharmaceutical sector, focusing on the development of cell therapy products. The company specializes in utilizing advanced technologies to enhance the efficacy of hematopoietic stem cell transplantation.
Product Pipeline
Gamida Cell's lead product candidate is NiCord, a treatment aimed at improving the outcomes of patients with blood cancers and other hematological disorders through the use of enhanced umbilical cord blood-derived stem cells.
| Product | Indication | Phase of Development | Expected Milestone |
|---|---|---|---|
| NiCord | Hematological Malignancies | Phase 3 | 2024 FDA submission |
| GDA-201 | Acute Myeloid Leukemia | Phase 1/2 | 2023 initial data release |
Financial Performance
As of the latest financial report for Q3 2023, Gamida Cell reported a cash and cash equivalents balance of $23 million and total revenue of $4.2 million. The net loss for the same period was $12.5 million.
| Financial Metric | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|
| Cash and Cash Equivalents | $23 million | $30 million | $37 million |
| Total Revenue | $4.2 million | $3.5 million | $2.8 million |
| Net Loss | $12.5 million | $10 million | $9 million |
Market Opportunities
The global stem cell therapy market is projected to grow at a CAGR of 10.3% from 2023 to 2030, reaching an estimated value of $200 billion by 2030. Gamida Cell aims to position itself strategically within this expanding market.
Partnerships and Collaborations
Gamida Cell maintains collaborations with leading research institutions and pharmaceutical companies to enhance its product development capabilities. Key partnerships include:
- Bristol-Myers Squibb
- NIH Cell Therapy Program
- University of Pennsylvania
Regulatory Pathways
The company focuses on adhering to regulatory guidelines set by the FDA and EMA, working diligently towards gaining necessary approvals for its product candidates.
Research and Development Investments
Gamida Cell invested approximately $8 million in R&D during the first half of 2023, reflecting its commitment to innovation and product advancement.
Stock Performance
As of October 2023, the stock price of Gamida Cell (GMDA) was trading at approximately $2.50, with a market capitalization of around $150 million.
| Date | Stock Price | Market Capitalization | Volume |
|---|---|---|---|
| October 2023 | $2.50 | $150 million | 500,000 |
| September 2023 | $2.00 | $120 million | 600,000 |
Future Outlook
Gamida Cell aims to secure FDA approval for NiCord, expand its clinical trials portfolio, and potentially increase its market share in the burgeoning field of cell therapies.
How Gamida Cell Ltd. (GMDA) Makes Money
Revenue Streams
Gamida Cell Ltd. (GMDA) generates revenue from several key areas, primarily focusing on cell therapy products. The company's lead product candidate is NiCord, which is designed for patients with hematologic malignancies.
Product Development and Commercialization
GMDA is engaged in the commercialization of its product candidates after receiving regulatory approvals. The company aims to bring its therapies to market, focusing on treatments for blood cancers and other diseases that require stem cell transplants.
Partnerships and Collaborations
Strategic partnerships enhance GMDA's financial positions. These collaborations can lead to milestone payments, research funding, and royalties on future sales. In 2022, GMDA entered into a collaboration with Novartis, potentially generating up to $100 million in milestone payments.
Current Financial Performance
As of the latest financial report in Q3 2023, Gamida Cell reported revenues of approximately $3 million from research and development collaborations, primarily from the partnership with Novartis.
Funding and Investment
GMDA has raised significant capital through public offerings. In 2021, the company completed a public offering that raised approximately $60 million. These funds are crucial for ongoing clinical trials and operational costs.
Operating Expenses
In 2023, the company reported operating expenses totaling $28 million, reflecting the costs associated with research and development, administrative expenses, and manufacturing related to its product candidates.
Clinical Trials and Regulatory Milestones
Clinical trials are vital for GMDA's revenue potential. Current trials for NiCord may lead to regulatory approvals, which could result in substantial revenue inflows. Successful completion can trigger milestone payments from collaborators.
| Year | Revenue (in millions) | Operating Expenses (in millions) | Net Loss (in millions) |
|---|---|---|---|
| 2021 | 2.5 | 18 | (15.5) |
| 2022 | 2.8 | 24 | (21.2) |
| 2023 | 3.0 | 28 | (25.0) |
Future Revenue Opportunities
Gamida Cell is planning to expand its pipeline with additional product candidates. Potential future revenues may come from new therapies targeting other types of cancer and hematological disorders.
Market Capitalization
As of October 2023, Gamida Cell's market capitalization stands at approximately $250 million. This valuation reflects investor sentiment regarding the potential of its product pipeline and strategic partnerships.
Conclusion on Financial Outlook
Though GMDA is currently in a net loss position, the potential for future revenues through product commercialization, strategic partnerships, and clinical advancements remain critical components of its financial strategy.
Gamida Cell Ltd. (GMDA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support